Apellis Pharmaceuticals, Inc. — Director's Dealing 2022

Jul 18, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2022-07-15

Reporting Person: Machiels Alec (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-07-15	Common Stock	M	1250	$2.67	Acquired	265024	Direct
2022-07-15	Common Stock	S	1250	$46.33	Disposed	263774	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-07-15	Stock Option (Right to Buy)	$2.67	M	1250	Disposed	2023-12-04	Common Stock (1250)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	250000	Indirect
Common Stock	11950	Indirect
Common Stock	150000	Indirect

Footnotes

F1: This is a scheduled exercise and sale from 10B5-1 trading plan.

F2: Owned by spouse.

F3: This option was granted on December 5, 2013 and fully vested.